Biogen (Nasdaq: BIIB) announced that its New Drug Application (NDA) for nusinersen, an investigational treatment for spinal muscular atrophy (SMA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE